The U.S. Food and Drug Administration has escalated its crackdown on misleading pharmaceutical and telehealth advertisements by releasing around 100 warning letters to firms including major drugmakers and telehealth providers. The scrutiny focuses on inaccurate risk-benefit presentations and unapproved claims, signaling a strengthened regulatory stance. Industry experts note resource constraints but acknowledge the FDA’s intent to prioritize enforcement actions. This initiative advances transparency and consumer protection amid growing digital marketing complexities in healthcare.